Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
MARUPECHE from Brugge, company number BE0876581872, closed financial year 2025 with a result of € -144 after tax. For that financial year MARUPECHE recorded a gross margin of € 0 and equity of € -126,312. Compared with financial year 2024, the result moved from € -113,034 to € -144. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ -126,312
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -144
▲ 100 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.1 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 18
▲ € 17 vs 2024
Loans from banks and other lenders, long and short.
€ 3,210
▼ 99% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 118,246
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 493 | € 1,300 | € 6,920 | € 0 | ▼ 100% |
| Profit after taxes | € 305 | € -6,855 | € -113,034 | € -144 | ▲ € 112,890 |
| Equity | € -6,278 | € -13,133 | € -126,168 | € -126,312 | |
| Total debts | € 8,121 | € 13,171 | € 434,404 | € 126,349 | ▼ 71% |
| Cash | € 390 | € 0 | - | - | |
| Retained profit | € -1,006,278 | € -1,013,133 | € -1,126,168 | € -1,126,312 | |
| Bank debt | € 0 | € 19 | € 0 | € 18 | ▲ € 17 |
| Balance sheet total | € 1,843 | € 37 | € 308,236 | € 37 | ▼ € 308,199 |
Key figures of MARUPECHE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to MARUPECHE?
What happened at MARUPECHE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Bruno Coornaert stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 144. filed late Source: NBB ↗
- Bruno Coornaert became a director. NBB
- New establishment in Brugge. KBO
- Start of the company according to the CBE. KBO
In short
From € 305 profit in 2022 to € 144 loss in 2025.
Paid € 6,910 in corporate taxes since 2022.
Best year ever: 2022, with € 305 profit.
Management
Directors
According to the 2025 annual accounts
Bruno Coornaert
Director
since 2022 · until 2031
Establishments
Establishment units
Physical locations of this company
Baron Ruzettelaan 1 box 0.1
8310 Brugge
Baron Ruzettelaan 5 box 1.2.
8310 Brugge
Active since 14 November 2005
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0876.581.872
- VAT number
- BE 0876.581.872
- Registered office
- Baron Ruzettelaan 1 bus 0.1, 8310 Brugge
- Names & denominations
- MARUPECHE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 October 2005
- Peppol
- Active · Active since 7 Jan 2026
- Activities · NACE
Groothandel in diepvriesproducten
Niet-gespecialiseerde groothandel in diepgevroren voedingsmiddelen
Activiteiten van holdings
Niet-gespecialiseerde groothandel in niet-diepgevroren voedingsmiddelen, dranken en genotmiddelen
Managementactiviteiten van holdings
Overige niet-gespecialiseerde groothandel in voedings- en genotmiddelen
Holdings